Compare IMUX & PGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMUX | PGP |
|---|---|---|
| Founded | 2016 | 2003 |
| Country | United States | United States |
| Employees | 66 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.2M | 93.8M |
| IPO Year | 2013 | 2005 |
| Metric | IMUX | PGP |
|---|---|---|
| Price | $7.24 | $7.96 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $42.64 | N/A |
| AVG Volume (30 Days) | ★ 248.3K | 43.2K |
| Earning Date | 11-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.84% |
| EPS Growth | ★ 38.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.51 | $7.95 |
| 52 Week High | $17.43 | $9.41 |
| Indicator | IMUX | PGP |
|---|---|---|
| Relative Strength Index (RSI) | 40.86 | 38.64 |
| Support Level | $6.35 | N/A |
| Resistance Level | $8.41 | $8.87 |
| Average True Range (ATR) | 0.55 | 0.15 |
| MACD | 0.11 | -0.00 |
| Stochastic Oscillator | 11.81 | 4.35 |
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
PIMCO Global Stocksplus & Income Fund is a closed-end management investment company. The objective of the fund is to seek a total return comprised of current income, current gains, as well as long-term capital appreciation. The fund invests a majority of the fund's net assets in a combination of securities and instruments that provide exposure to stocks and or produce income.